| AEPCX | CIESX | AEPCX / CIESX | |
| Total Expense Ratio | 1.58 | 0.85 | 186% |
| Annual Report Gross Expense Ratio | 1.58 | 0.88 | 180% |
| Fund Existence | 25 years | 7 years | - |
| Gain YTD | 3.168 | 10.509 | 30% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 250 | 5000000 | 0% |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 141B | 835M | 16,886% |
| Annual Yield % from dividends | 2.13 | 1.14 | 187% |
| Returns for 1 year | 6.78 | 16.37 | 41% |
| Returns for 3 years | 14.70 | 30.62 | 48% |
| Returns for 5 years | -7.30 | 15.52 | -47% |
| Returns for 10 years | 38.82 | N/A | - |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| SLGYX | 23.05 | 0.19 | +0.83% |
| Saratoga Large Capitalization Growth A | |||
| JHAAX | 10.71 | 0.01 | +0.09% |
| JHancock Multi-Asset Absolute Return A | |||
| PCGRX | 28.71 | -0.07 | -0.24% |
| Victory Pioneer Mid Cap Value A | |||
| ECASX | 25.03 | -0.16 | -0.64% |
| Eaton Vance Atlanta Capital SMID-Cap C | |||
| FBTIX | 49.83 | -1.21 | -2.37% |
| Fidelity Advisor Biotechnology I | |||